STUDY AIMS OVERVIEW
CHARTER’s major aims are to determine how central and peripheral nervous system complications of HIV are affected by different histories and regimens of antiretroviral therapy (ART). Participants receive comprehensive neuromedical, neurocognitive, and laboratory examinations, with a subset undergoing host/viral genetic characterization and neuroimaging.
In September 2007, the Option Period of CHARTER began. The Option Period was an opportunity to take findings from the initial study period and refine the study to focus on current areas of interest in neuroAIDS. To this end the Option Period will focus on these four major areas: host genetics, viral genetics, peripheral neuropathy, and white matter disease . In addition, we will take advantage of the CHARTER infrastructure and population to begin characterizing the effects of newly emerging ARV treatments on HAND, and to characterize the neurologic profiles of the subset of early/acute infection cases that have become available to us.
In September 2010, The CHARTER Extension began. In the Extension, the CHARTER aims were further refined to focus on how extended follow-up of a select number of CHARTER participants could provide further insight into the effects of low-level viral replication in the CNS, predictors of neurocognitive and neuroimaging worsening, and the reversibility of nerve injury in the context of ART.